benzonidazole has been researched along with fenofibrate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cevey, ÁC; Donato, M; Gelpi, RJ; Goren, NB; Mirkin, GA; Penas, FN; Rada, MJ | 1 |
2 other study(ies) available for benzonidazole and fenofibrate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Diastole; Fenofibrate; Fibrosis; Humans; Inflammation; Interleukin-6; Mice; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide Synthase Type II; Nitroimidazoles; PPAR alpha; Stroke Volume; Trypanocidal Agents; Trypanosoma cruzi; Tumor Necrosis Factor-alpha; Ventricular Dysfunction; Ventricular Function | 2017 |